Belite Bio Inc ADR (US: BLTE) — Healthcare · Share Price, Chart & Market Data
About: Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.
Sector: Healthcare
Industry: Biotechnology
Latest price: $161.26 (-1.94%)
BLTEBelite Bio Inc ADR
Loading watchlist status…
Trade BLTE now
Belite Bio Inc ADR share price
BLTE price activity
Last Price
Change (24hr)
USD (%)
Volume
Volume (4w avg)
Previous Close
N/A
Last Trade
Delayed
27 Apr, 11:13 am GMT+0
BLTE price performance
-2.403%
5D
6.043%
1M
1.249%
YTD
167.963%
1Y
BLTE price fundamentals
N/A
Shares Issued
N/A
Dividends Per Share (DPS)
N/A
Earnings Per Share (EPS)
N/A
P/E Ratio
Price market cap
Market cap
N/A
US rank
N/A
Sector Rank
N/A
Delayed
27 Apr, 11:13 am GMT+0
BLTE details
BLTE Market Signals